RVNC•benzinga•
Barclays Maintains Equal-Weight on Revance Therapeutics, Lowers Price Target to $3
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 23, 2024 by benzinga